<p>Alpha Teknova（納斯達克代碼：TKNO - 獲取免費報告）在週三發佈的研究報告中被 Zacks Research 的股票分析師上調至 “持有” 評級，Zacks.com 報道。</p>
<p>獲取 <strong>Alpha Teknova</strong> 警報：</p>
<p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Alpha Teknova 股票的 “賣出（d-）” 評級。一位研究分析師給予該股票強烈買入評級，一位給予買入評級，一位給予持有評級，還有一位給予賣出評級。根據 MarketBeat 的數據，Alpha Teknova 目前的平均評級為 “適度買入”，共識目標價為 10.00 美元。</p>
<p><strong>閲讀我們最新的 TKNO 股票分析</strong></p>
<h2>Alpha Teknova 股票上漲 1.7%</h2>
<p>週三 TKNO 股票開盤價為 4.89 美元。Alpha Teknova 的年低為 3.94 美元，年高為 10.37 美元。該公司的市值為 2.6176 億美元，市盈率為-13.97，貝塔值為 0.40。該公司的 50 日移動平均價格為 4.95 美元，200 日移動平均價格為 4.97 美元。公司的債務與股本比率為 0.18，速動比率為 4.27，流動比率為 5.27。</p>
<p>Alpha Teknova（納斯達克代碼：TKNO - 獲取免費報告）最後一次發佈財報是在 11 月 6 日，報告顯示該季度每股收益（EPS）為（0.08 美元），超出市場共識預期的（0.09 美元）0.01 美元。Alpha Teknova 的股本回報率為-23.53%，淨利潤率為-45.78%。該公司在該季度的收入為 1045 萬美元，而分析師預期為 1023 萬美元。平均而言，股票研究分析師預計 Alpha Teknova 在當前年度將發佈-0.58 的每股收益。</p>
<h2>機構投資者對 Alpha Teknova 的看法</h2>
<p>幾家大型投資者最近增加或減少了對該公司的投資。Walleye Capital LLC 在第一季度購買了 Alpha Teknova 的新股份，價值約為 88,000 美元。OMERS ADMINISTRATION Corp 在第一季度將其在 Alpha Teknova 的股份提高了 101.2%。OMERS ADMINISTRATION Corp 現在擁有 80,700 股該公司的股票，價值 419,000 美元，此前在上個季度又購買了 40,600 股。Alpine Global Management LLC 在第一季度購買了 Alpha Teknova 的新股份，價值 128,000 美元。高盛集團在第一季度將其在 Alpha Teknova 的股份提高了 68.3%。高盛集團現在擁有 90,595 股該公司的股票，價值 470,000 美元，此前在此期間又購買了 36,763 股。最後，McAdam LLC 在第一季度收購了 Alpha Teknova 的新股份，價值約為 60,000 美元。對沖基金和其他機構投資者持有該股票的 13.81%。</p>
<h2>Alpha Teknova 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Alpha Teknova, Inc 在美國和國際上生產用於研究、發現、開發和商業化新療法、疫苗和分子診斷的關鍵試劑。該公司提供用於細胞生長和克隆的預製培養基板；用於細胞擴增的液體細胞培養基和補充劑；以及用於樣本操作、重懸和純化的分子生物學試劑。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Alpha Teknova</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>2026 年應避免的三隻最近被下調評級的股票</li>
<li>如何從價值投資中獲利</li>
<li>芯片熱潮迴歸：三隻有巨大收益潛力的股票</li>
<li>除了喝咖啡，還有三種投資咖啡的方法</li>
<li>甲骨文股票遭重創：為何其 AI 管道可能推動 2026 年反彈</li>
</ul>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Alpha Teknova 嗎？</h2>
<p>在考慮 Alpha Teknova 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Alpha Teknova 並不在名單上。</p>
<p>雖然 Alpha Teknova 目前在分析師中有適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TKNO

<p>Zacks Research 將 Alpha Teknova 的評級上調至 “持有”，而 Weiss Ratings 重申了 “賣出” 評級。該股票的平均評級為適度買入，目標價格共識為 10.00 美元。TKNO 股票上漲 1.7%，至 4.89 美元。Alpha Teknova 報告的收益好於預期，淨利潤率為負 45.78%。機構投資者已調整了在該公司的持股。Alpha Teknova 生產用於新療法和診斷的試劑</p>

<p>Alpha Teknova (NASDAQ:TKNO - Get Free Report) was upgraded by stock analysts at Zacks Research to a &#34;hold&#34; rating in a research report issued on Wednesday,Zacks.com reports.</p>
<div class="lb-trans"><p>Alpha Teknova（納斯達克代碼：TKNO - 獲取免費報告）在週三發佈的研究報告中被 Zacks Research 的股票分析師上調至 “持有” 評級，Zacks.com 報道。</p>
</div><p>Get <strong>Alpha Teknova</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Alpha Teknova</strong> 警報：</p>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Alpha Teknova in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Alpha Teknova presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $10.00.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Alpha Teknova 股票的 “賣出（d-）” 評級。一位研究分析師給予該股票強烈買入評級，一位給予買入評級，一位給予持有評級，還有一位給予賣出評級。根據 MarketBeat 的數據，Alpha Teknova 目前的平均評級為 “適度買入”，共識目標價為 10.00 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on TKNO</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 TKNO 股票分析</strong></p>
</div><h2>Alpha Teknova Stock Up 1.7%</h2>
<div class="lb-trans"><h2>Alpha Teknova 股票上漲 1.7%</h2>
</div><p>TKNO stock opened at $4.89 on Wednesday. Alpha Teknova has a one year low of $3.94 and a one year high of $10.37. The firm has a market cap of $261.76 million, a PE ratio of -13.97 and a beta of 0.40. The firm's 50 day moving average price is $4.95 and its 200-day moving average price is $4.97. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.27 and a current ratio of 5.27.</p>
<div class="lb-trans"><p>週三 TKNO 股票開盤價為 4.89 美元。Alpha Teknova 的年低為 3.94 美元，年高為 10.37 美元。該公司的市值為 2.6176 億美元，市盈率為-13.97，貝塔值為 0.40。該公司的 50 日移動平均價格為 4.95 美元，200 日移動平均價格為 4.97 美元。公司的債務與股本比率為 0.18，速動比率為 4.27，流動比率為 5.27。</p>
</div><p>Alpha Teknova (NASDAQ:TKNO - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. Alpha Teknova had a negative return on equity of 23.53% and a negative net margin of 45.78%.The company had revenue of $10.45 million during the quarter, compared to analysts' expectations of $10.23 million. On average, equities research analysts anticipate that Alpha Teknova will post -0.58 EPS for the current year.</p>
<div class="lb-trans"><p>Alpha Teknova（納斯達克代碼：TKNO - 獲取免費報告）最後一次發佈財報是在 11 月 6 日，報告顯示該季度每股收益（EPS）為（0.08 美元），超出市場共識預期的（0.09 美元）0.01 美元。Alpha Teknova 的股本回報率為-23.53%，淨利潤率為-45.78%。該公司在該季度的收入為 1045 萬美元，而分析師預期為 1023 萬美元。平均而言，股票研究分析師預計 Alpha Teknova 在當前年度將發佈-0.58 的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Alpha Teknova</h2>
<div class="lb-trans"><h2>機構投資者對 Alpha Teknova 的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the business. Walleye Capital LLC purchased a new position in shares of Alpha Teknova in the 1st quarter valued at about $88,000. OMERS ADMINISTRATION Corp lifted its stake in Alpha Teknova by 101.2% in the first quarter. OMERS ADMINISTRATION Corp now owns 80,700 shares of the company's stock valued at $419,000 after buying an additional 40,600 shares during the last quarter. Alpine Global Management LLC purchased a new stake in Alpha Teknova in the 1st quarter valued at $128,000. Goldman Sachs Group Inc. boosted its stake in shares of Alpha Teknova by 68.3% during the first quarter. Goldman Sachs Group Inc. now owns 90,595 shares of the company's stock worth $470,000 after buying an additional 36,763 shares during the period. Finally, McAdam LLC acquired a new stake in Alpha Teknova during the 1st quarter worth approximately $60,000. 13.81% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家大型投資者最近增加或減少了對該公司的投資。Walleye Capital LLC 在第一季度購買了 Alpha Teknova 的新股份，價值約為 88,000 美元。OMERS ADMINISTRATION Corp 在第一季度將其在 Alpha Teknova 的股份提高了 101.2%。OMERS ADMINISTRATION Corp 現在擁有 80,700 股該公司的股票，價值 419,000 美元，此前在上個季度又購買了 40,600 股。Alpine Global Management LLC 在第一季度購買了 Alpha Teknova 的新股份，價值 128,000 美元。高盛集團在第一季度將其在 Alpha Teknova 的股份提高了 68.3%。高盛集團現在擁有 90,595 股該公司的股票，價值 470,000 美元，此前在此期間又購買了 36,763 股。最後，McAdam LLC 在第一季度收購了 Alpha Teknova 的新股份，價值約為 60,000 美元。對沖基金和其他機構投資者持有該股票的 13.81%。</p>
</div><h2>Alpha Teknova Company Profile</h2>
<div class="lb-trans"><h2>Alpha Teknova 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.</p>
<div class="lb-trans"><p>Alpha Teknova, Inc 在美國和國際上生產用於研究、發現、開發和商業化新療法、疫苗和分子診斷的關鍵試劑。該公司提供用於細胞生長和克隆的預製培養基板；用於細胞擴增的液體細胞培養基和補充劑；以及用於樣本操作、重懸和純化的分子生物學試劑。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Alpha Teknova</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>How to Profit From Value Investing</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Alpha Teknova</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>2026 年應避免的三隻最近被下調評級的股票</li>
<li>如何從價值投資中獲利</li>
<li>芯片熱潮迴歸：三隻有巨大收益潛力的股票</li>
<li>除了喝咖啡，還有三種投資咖啡的方法</li>
<li>甲骨文股票遭重創：為何其 AI 管道可能推動 2026 年反彈</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alpha Teknova Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Alpha Teknova 嗎？</h2>
</div><p>Before you consider Alpha Teknova, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Alpha Teknova 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Teknova wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Alpha Teknova 並不在名單上。</p>
</div><p>While Alpha Teknova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Alpha Teknova 目前在分析師中有適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Alpha Teknova（納斯達克股票代碼：TKNO）在 Zacks Research 被上調評級